RNS Number : 7595Q
N4 Pharma PLC
14 July 2025

14 July 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

Investor Webinar

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that Nigel Theobald, Chief Executive Officer,will provide a strategic update on the Company's ongoing development of Nuvec® as a delivery system for RNA therapeutics on Tuesday, 22 July 2025 at 10.00 am via the Investor Meet Company Platform.

Nigel will be joined by members of the Senior Leadership Team, including Dr Mark Edbrooke, Head of Strategy, who will present on *The RNA Therapeutics Revolution*, and Dr Fiona McLaughlin, Head of Research and Development, who will present on *Established Delivery Platforms and the Key Benefits of Nuvec®*.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00 am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:

https://www.investormeetcompany.com/n4-pharma-plc/register-investor

Investors who already follow N4 Pharma plc on the Investor Meet Company platform will automatically be invited.

- Ends -

For more information please contact:

N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director	Via N4 Pharma Investor Hub:investors.n4pharma.com
Submit your questions directly to the management team via the N4 Pharma Investor Hub	https://n4pharma.com/link/eW32ae
SP Angel CorporateFinance LLP *Nominated Adviser and Joint Broker* Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited *Joint Broker*	Tel: +44 (0)20 3657 0050

Andy Thacker
James Pope

Northstar Communications Limited Tel: +44 (0)113 730 3896
Investor Relations
Sarah Hollins

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®,its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with commercial partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

For further information on the Company visitwww.n4pharma.comor sign up athttps://investors.n4pharma.com/auth/signup.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEANXFFLLSEEA